Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Denali, a biotech company, received a $500 million investment after facing setbacks in a clinical trial for an ALS drug. Viking presented data suggesting their obesity drug could rival those from Eli Lilly and Novo Nordisk. Janux's shares tripled after positive results for their cancer immunotherapy drug. Minerva's schizophrenia drug was rejected by the FDA.Transitioning to the next news, Viking Therapeutics achieved a significant milestone in their obesity drug development with positive results from a Phase II study showing patients losing up to nearly 15% of their weight in three months. However, Minerva Neurosciences faced a setback as their schizophrenia treatment candidate was rejected by the FDA due to lack of data and other factors. Moving on, Denali Therapeutics secured $500 million in financing, Biomarin Pharmaceuticals received a subpoena from the Department of Justice, and Merck's drug Bridion could face generic competition from Hikma. Novo Nordisk also signed a potential $1.46 billion deal with Neomorph for their molecular glue platform. Additionally, Janux's stock soared after positive results from two candidates in Phase I trials. Biopharma companies like Denali, Galapagos, and Adaptive have announced layoffs as part of their restructuring efforts.The article also discusses trends in obesity drug treatments and strategies for improving engagement with healthcare professionals using AI-powered data. Additionally, the article highlights upcoming webinars on omnichannel HCP engagement and filling roles in life sciences. Biopharma Dive provides news and insights on the biotech and pharma industry, covering topics like clinical trials, FDA approvals, gene therapy, drug pricing, and research partnerships.